Terms: = Lung cancer AND LMO2, RBTN2, 4005, ENSG00000135363, P25791, TTG2, RBTNL1, RHOM2
17 results:
1. LDCT screening results among eligible and ineligible screening candidates in preventive health check-ups population: a real world study in West China.
Bao T; Liu B; Li R; Li Z; Ji G; Wang Y; Yang H; Li W; Huang W; Huang Y; Tang H
Sci Rep; 2024 Feb; 14(1):4848. PubMed ID: 38418532
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell lung cancer.
Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
[TBL] [Abstract] [Full Text] [Related]
3. Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
Mukhopadhyay S; Huang HY; Lin Z; Ranieri M; Li S; Sahu S; Liu Y; Ban Y; Guidry K; Hu H; Lopez A; Sherman F; Tan YJ; Lee YT; Armstrong AP; Dolgalev I; Sahu P; Zhang T; Lu W; Gray NS; Christensen JG; Tang TT; Velcheti V; Khodadadi-Jamayran A; Wong KK; Neel BG
Cancer Res; 2023 Dec; 83(24):4095-4111. PubMed ID: 37729426
[TBL] [Abstract] [Full Text] [Related]
4. lmo2 attenuates glycolytic metabolism and facilitates cytotoxic T-lymphocyte infiltration in the tumor environment of lung and breast cancers.
Wang W; Meng Y; Yu Y; Wang H; Sun W
Biochem Biophys Res Commun; 2023 Oct; 675():170-176. PubMed ID: 37480698
[TBL] [Abstract] [Full Text] [Related]
5. Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma.
Shi DM; Dong SS; Zhou HX; Song DQ; Wan JL; Wu WZ
Cell Signal; 2023 Apr; 104():110565. PubMed ID: 36539000
[TBL] [Abstract] [Full Text] [Related]
6. Identification of a minority population of lmo2
Sikandar SS; Gulati GS; Antony J; Fetter I; Kuo AH; Ho WHD; Haro-Acosta V; Das S; Steen CB; Pereira TA; Qian D; Beachy PA; Dirbas FM; Red-Horse K; Rabbitts TH; Thiery JP; Newman AM; Clarke MF
Sci Adv; 2022 Nov; 8(45):eabm3548. PubMed ID: 36351009
[TBL] [Abstract] [Full Text] [Related]
7. Survival analysis in lung cancer patients with interstitial lung disease.
Alomaish H; Ung Y; Wang S; Tyrrell PN; Zahra SA; Oikonomou A
PLoS One; 2021; 16(9):e0255375. PubMed ID: 34492020
[TBL] [Abstract] [Full Text] [Related]
8. The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
Qi M; Bian D; Zhang J; Zhu X; Zhou C; Zhang L
Lung Cancer; 2021 Aug; 158():47-54. PubMed ID: 34119932
[TBL] [Abstract] [Full Text] [Related]
9. A Prospective Trial to Compare Deep Inspiratory Breath Hold With Prone Breast Irradiation.
Gerber NK; Yan SX; Levinson BA; Perez CA; Das IJ; Maisonet OG; Huppert N; No DK; Kelley J; Mistry N; Hitchen CJ; Goldberg JD
Pract Radiat Oncol; 2020; 10(5):330-338. PubMed ID: 32014615
[TBL] [Abstract] [Full Text] [Related]
10. A hybrid expert approach for retrospective assessment of occupational exposures in a population-based case-control study of cancer.
Sauvé JF; Lavoué J; Nadon L; Lakhani R; Senhaji Rhazi M; Bourbonnais R; Richard H; Parent MÉ
Environ Health; 2019 Feb; 18(1):14. PubMed ID: 30770757
[TBL] [Abstract] [Full Text] [Related]
11. Chromatin accessibility changes are associated with enhanced growth and liver metastasis capacity of acid-adapted colorectal cancer cells.
Zhou ZH; Wang QL; Mao LH; Li XQ; Liu P; Song JW; Liu X; Xu F; Lei J; He S
Cell Cycle; 2019 Feb; 18(4):511-522. PubMed ID: 30712429
[TBL] [Abstract] [Full Text] [Related]
12. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell lung cancer
Naz S; Sowers A; Choudhuri R; Wissler M; Gamson J; Mathias A; Cook JA; Mitchell JB
Clin Cancer Res; 2018 Aug; 24(16):3994-4005. PubMed ID: 29716919
[No Abstract] [Full Text] [Related]
13. Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan.
Momo K; Takagi A; Miyaji A; Koinuma M
Pulm Pharmacol Ther; 2018 Jun; 50():88-92. PubMed ID: 29627482
[TBL] [Abstract] [Full Text] [Related]
14. Foxp3 downregulation in NSCLC mediates epithelial-mesenchymal transition via NF-κB signaling.
Wang X; Liu Y; Dai L; Liu Q; Jia L; Wang H; An L; Jing X; Liu M; Li P; Cheng Z
Oncol Rep; 2016 Oct; 36(4):2282-8. PubMed ID: 27574108
[TBL] [Abstract] [Full Text] [Related]
15. Identification of potential therapeutic targets for lung cancer by bioinformatics analysis.
Wang LQ; Zhao LH; Qiao YZ
Mol Med Rep; 2016 Mar; 13(3):1975-82. PubMed ID: 26739332
[TBL] [Abstract] [Full Text] [Related]
16. [Adenocystic bronchial cancer].
Parshin VD; Biriukov IuV; Grigor'eva SP; Vishnevskaia GA
Khirurgiia (Mosk); 2007; (5):26-31. PubMed ID: 17690676
[TBL] [Abstract] [Full Text] [Related]
17. The LIM-domain protein lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
[TBL] [Abstract] [Full Text] [Related]
